'Street Underestimates Jazz Pharma's Cash-Flow'

 

• HC Wainwright tweaked the price target on Jazz Pharmaceuticals plc 
  JAZZ+1.69%+ Free Alerts
   to $204 with a reiterated Buy rating on slightly increased forward EPS estimates.
• Jazz reported a thorough 2Q22 beat, with broad product outperformance vs. consensus across neuro and oncology, plus gross margin upside and light OPEX, HC Wainwright notes.
• As per the analyst, this looked to be Jazz’s second-biggest operating cash flow quarter ever, pushing net leverage down to 3.2x, six months ahead of the targeted <3.5x by year-end. 
• Xywav is adding idiopathic hypersomnia patients slightly faster than modeled, and Rylaze adoption has ramped much faster than expected, the analyst writes.
• HC Wainwright believes the Street underestimates Jazz’s cash-flow generation through limited Xyrem AG competitive entry.
• Further, Jazz’s cash flow positions the balance sheet to move on significant accretive and diversifying M&A. 

https://www.benzinga.com/general/biotech/22/08/28379865/street-underestimates-jazz-pharmas-cash-flow-says-this-analyst